Shares of Aurobindo Pharma (AUROBIND.NSE) climbed 0.6% to ₹1,681.8 after the firm announced the US launch of Adquey, its first novel dermatology drug, with a net present value of ₹40 per share.
Adquey, a non‑steroidal topical phosphodiesterase‑4 inhibitor, targets mild‑to‑moderate atopic dermatitis in patients as young as two years old. IQVIA MAT estimates the 12‑month US market for this class at roughly $1.3 billion, with the drug protected by a patent that expires in 2036.
Brokerage Nuvama projects peak sales of about $300 million for Adquey, citing the size of the dermatology segment and the drug’s therapeutic niche. The firm also values the launch at ₹40 per share, and maintains a Buy rating with a ₹1,840 target, implying a 10% upside from today’s close.
Analysts tracking Aurobindo are split: 18 of 28 recommend Buy, the rest hold or sell, and the stock has surged 41% YTD. The lift follows a series of product introductions in penicillin G, inhalers, controlled substances and small branded generics, showing a broadening portfolio.
Looking ahead, Nuvama expects Aurobindo to tap peptides, biosimilars, biologics and contract manufacturing, which could further elevate the company’s valuation. The next earnings report is slated for November 2026, where investors will gauge the impact of Adquey’s first‑quarter sales.